Discontinued — last reported Q3 '25
Corpay Equity Method Investments decreased by 2.5% to $586.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 836.1%, from $62.67M to $586.70M. Over 5 years (FY 2020 to FY 2025), Equity Method Investments shows an upward trend with a 140.5% CAGR.
An increase indicates strategic expansion through partnerships or joint ventures, while a decrease may signal divestments or impairment.
These are investments in entities where the company exercises significant influence but does not have full control. The...
Varies significantly based on corporate strategy; common in healthcare companies that partner with biotech startups or specialized diagnostic firms.
equity_method_investments| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $11.86M | $11.86M | $52.02M | $71.06M | $67.07M | $74.35M | $74.28M | $67.59M | $69.72M | $67.96M | $69.52M | $68.30M | $64.04M | $64.61M | $60.09M | $62.67M | $58.32M | $58.68M | $601.94M | $586.70M |
| QoQ Change | — | +0.0% | +338.7% | +36.6% | -5.6% | +10.9% | -0.1% | -9.0% | +3.2% | -2.5% | +2.3% | -1.8% | -6.2% | +0.9% | -7.0% | +4.3% | -6.9% | +0.6% | +925.8% | -2.5% |
| YoY Change | — | — | — | — | +465.6% | +527.0% | +42.8% | -4.9% | +4.0% | -8.6% | -6.4% | +1.1% | -8.1% | -4.9% | -13.6% | -8.2% | -8.9% | -9.2% | +901.8% | +836.1% |